Theravance Biopharma Inc · Pharmaceuticals
$17.08
As of: 2026-09-04 04:41:59 (KST)
-28.5%
Expected return
33%
Success probability
-31.7%
Downside risk
For informational purposes only.
Not investment advice.
Theravance Biopharma Inc in the Pharmaceuticals industry carries C grade, driven by a Monte Carlo rating of 25. With an expected return of -28.5% and a 33% chance of positive returns, the stock at $17.08 presents This assessment is based on 10,000 probabilistic scenarios, offering a robust view of the potential return distribution across varying market conditions.
The Reverse DCF analysis places this stock in the "Expensive" zone. The implied growth rate (g_implied) of 30.7%, compared with the actual growth rate of 7.7%, reveals the market's pricing assumptions. The P50 intrinsic value sits at $12, offering a reference point against the current price. At $17, the Reverse-DCF implied probability of finishing above $17 stands at 1%.
This C rating (25) suggests caution. The expected return of -28.5% and 33% success probability are below our threshold for an attractive entry.
The Monte Carlo distribution reveals a volatility of 2.9% — relatively low, meaning the simulated outcomes cluster tightly around the median. The P50 sits at -29.1%, with a +4.9% gap between P10 (-31.7%) and P75 (-26.8%). a negative skew suggests downside scenarios are more pronounced than upside ones
In the worst 5% of scenarios, the 5th percentile value-at-risk is -31.7%. On the operating side, a solid 46.8% operating margin helps cushion downside scenarios. With a volatility of 2.9%, volatility risk is low at the current price of $17.
DCF estimates a company's intrinsic value by discounting its future cash flows to present value. Modelvix uses Monte Carlo simulation to analyze thousands of scenarios.
Learn more →WACC is the average rate a company pays to finance its assets, used as the discount rate in DCF analysis. Modelvix simulates how WACC changes affect valuation.
Learn more →Terminal value represents the perpetual value of a business beyond the forecast period, often comprising the majority of DCF value. Modelvix analyzes terminal value uncertainty across growth scenarios.
Learn more →Reverse DCF works backward from the current stock price to infer the growth rate the market expects, helping you assess whether a stock is fairly valued. Modelvix shows what growth assumptions the current price implies.
Learn more →